Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1

Interventions

aldesleukin 24Cyclophosphamide 14Interferon-alpha 10fludarabine 8fludarabine phosphate 7Interleukin-2 6Chemotherapy, Adjuvant 6sargramostim 5Neoadjuvant Therapy 5Fluorouracil 4Vincristine 3Sunitinib 3Magnetic Resonance Spectroscopy 3Dactinomycin 3Carboplatin 3Bevacizumab 3Amplified Fragment Length Polymorphism Analysis 3vandetanib 2valspodar 2tanespimycin 2ixabepilone 2carboxyamido-triazole 2bryostatin 1 2Vinblastine 2Thalidomide 2Temozolomide 2Sorafenib 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Muromonab-CD3 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Kidney Neoplasms × guadecitabine × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡